Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356434 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29375252 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30307097 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL120703 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL799720 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29423588 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31697682 | 1.00 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| Hydrochloric Acid SCHEMBL6779156 | 0.99 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| Fluoride SCHEMBL7158848 | 0.99 | CASP3 (0.59) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29068310 | 0.95 | CASP3 (0.64) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013132262-A1 | PICROPODOPHYLLIN DERIVATIVES | AXELAR AB (SE) | 2013-09-12 | — | — | WO | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260115308-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | FORTVITA BIOLOGICS LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-3725798-B1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-12521444-B2 | Anti-HER2 antibody-drug conjugates and uses thereof | FORTVITA BIOLOGICS LIMITED (CN) | 2026-01-13 | — | — | US | disclosed |
| EP-4667495-A2 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-6544951-B2 | Antiinflammatory agents; autoimmune diseases, nervous system degradation | IDUN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020091089-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | KARANEWSKY DONALD S (US) | 2002-07-11 | — | — | US | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| CN-1313846-A | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases | IDUN PHARMACEUTICALS INC (US) | 2001-09-19 | — | — | CN | disclosed |
| US-6242422-B1 | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACUETICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| US-6197750-B1 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS | IDUN PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| US-5101059-A | Xanthene compounds | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| WO-1991008190-A1 | AMINO ACID PROTECTING GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | CASP3 1/4885KMT2A 4305/4885MDM4 2076/4885 |
| US-20020091089-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | CASP3 3/4885KMT2A 3895/4885MDM4 3015/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CASP3 1235/4885KMT2A 2654/4885MDM4 4129/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | CASP3 141/4885KMT2A 457/4885MDM4 669/4885 |
| US-20260115308-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ERBB2, FUT5, FUT6 | CASP3 1145/4885KMT2A 1065/4885MDM4 1617/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | CASP3 1/4885KMT2A 4310/4885MDM4 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.